Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR rate),progression free survival (PFS), duration of response (DOR) and overall survival(OS). The safety evaluation indicators are dose-limiting toxicity (DLT) , maximum tolerated dose (MTD)and recommended phase II dose (RP2D).

Trial Details

NCT ID
NCT06829771
Phase
PHASE1 / PHASE2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • TQB2825 injection +R-CHOP regimen
  • TQB2825 injection + GemOx
Locations (sample)
  • Bengbu, Anhui, China|32.94083,117.36083
  • Ma’anshan, Anhui, China|31.68579,118.51008
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Quanzhou, Fujian, China|24.91389,118.58583

Key Eligibility Criteria

  • Subjects voluntarily participate in this study, sign the informed consent form, and have good compliance;
  • Age 18 to under 80 years old (calculated from the date of signing the informed consent form);
  • Eastern Cooperative Oncology Group (ECOG) score of 0 to 2;
  • Life expectancy greater than 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →